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Abstract
Background: The goal was to forecast the global burden of Alzheimer’s disease and evaluate the
potential impact of interventions that delay disease onset or progression.
Methods: A stochastic multi-state model was used in conjunction with U.N. worldwide
population forecasts and data from epidemiological studies on risks of Alzheimer’s disease.
Findings: In 2006 the worldwide prevalence of Alzheimer’s disease was 26.6 million. By 2050,
prevalence will quadruple by which time 1 in 85 persons worldwide will be living with the
disease. We estimate about 43% of prevalent cases need a high level of care equivalent to that of
a nursing home. If interventions could delay both disease onset and progression by a modest 1
year, there would be nearly 9.2 million fewer cases of disease in 2050 with nearly all the decline
attributable to decreases in persons needing high level of care.
Interpretation: We face a looming global epidemic of Alzheimer’s disease as the world’s
population ages. Modest advances in therapeutic and preventive strategies that lead to even
small delays in Alzheimer’s onset and progression can significantly reduce the global burden of
the disease.
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INTRODUCTION
As the world population ages, enormous resources will be required to adequately care for
persons afflicted with Alzheimer’s disease. Research is actively underway to develop
interventions to both delay disease onset and slow progression of disease. Effective interventions
may significantly reduce the prevalence and incidence of Alzheimer’s disease, improve the
quality of life both of the patients and their caregivers, and reduce the resources needed to
provide adequate institutional and home health care. Several treatments to help slow disease
progression, and prevention strategies including lifestyle changes are being investigated (1).
Uncertainty exists in the estimates of the global burden of Alzheimer’s disease and the
potential impact of interventions. Recently, Alzheimer’s Disease International, an international
consortium of Alzheimer’s associations, produced estimates of the worldwide prevalence of
people with dementia (2). These estimates were based on a Delphi consensus study of 12
international experts who systematically reviewed published studies. The consensus method
involved a qualitative assessment of evidence by each expert, and then those experts were given
an opportunity to revise their estimates of prevalence after reflecting on the input of their
colleagues. The resulting Delphi consensus estimates have been considered some of the best
currently available estimates of worldwide prevalence. Yet, because the Delphi approach is not
based on an underlying quantitative model, the Delphi study cannot be readily used to forecast
the potential impact of new interventions on health care needs. Furthermore the study did not
take into account the severity of disease. Disease severity is an important consideration for
assessing the global burden of Alzheimer’s disease because the resources needed to care for
patients with advanced disease are very different than for patients early in the disease process.
The objective of this article is to forecast the global burden of Alzheimer’s disease based on a
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mathematical model that incorporates the aging of the world’s population. The model is used to
forecast the world-wide prevalence of Alzheimer’s disease, evaluate the impact of interventions,
and incorporate disease severity.

METHODS
The Multi-State Model
Our methodology is based on a multi-state probabilistic model for the incidence and
progression of Alzheimer’s’ disease. The method extends a single stage disease model used for
U.S. projections (3) by including early and late stages of disease. According to the model,
healthy persons have an annual probability of onset of Alzheimer’s disease which begins in an
early stage and ultimately progresses to late stage disease. Persons with early stage disease have
an annual probability of progressing to late stage disease. The definitions of early and late stage
disease including the mean durations are discussed below. Persons are at risk of death during
each state. The model is illustrated schematically in figure 1. The transition probabilities
between states are the probabilities of moving from one state to the next. We allow some of
these transition probabilities to depend not only on age but also calendar year to account both for
birth cohort effects (e.g. death rates change over time) and the impact of new interventions that
could potentially delay disease onset and progression. The model is implemented as a discrete
time stochastic model in which transitions occur only at the beginning of a calendar year, and it
is possible that persons may have multiple transitions in a year (e.g. disease onset followed by
death could occur in the same year).
We derived formulas for the age-specific prevalence rates of early stage and late stage
disease in terms of the model in figure 1. The transition probabilities are inputs into these
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formulas. We performed a number of analyses and systematic reviews of published literature, to
estimate the transition probabilities (described below.) Then, we forecast disease prevalence by
multiplying the formulas for age–specific prevalence rates by demographic population
projections. We used the United Nations worldwide population projections (4). Those
projections are in terms of 5 year age groups which we interpolated to obtain projections by
single year of age. We performed analyses separately by gender, and for each of six regions of
the world. Then, we evaluated the potential effects of interventions that delay disease onset,
delay disease progression or both by modifying the transition probabilities under different
scenarios. We multiplied the transition probabilities by various factors (relative risks) to model
the potential effects of the interventions. We translated these relative risks into average delays in
disease onset and progression (in the absence of competing causes of death) as an alternative
way to express the efficacy of intervention programs. We considered the impact of interventions
that begin in the year 2010. The technical details including the formulas for the age specific
prevalence rates and computing software are available from the authors at
www.biostat.jhsph.edu/project/globalAD/index.htm.

Transition Probabilities
In this section, we discuss inputs for each of the transition probabilities of figure 1.
Incidence rates
We estimated age-specific probabilities of disease onset by performing a systematic
review of published Alzheimer’s disease incidence rates. Jorm and colleagues (5) reviewed the
worldwide literature on Alzheimer’s disease incidence rates. We updated the Jorm review to
include additional recent studies reporting age-specific incidence rates of Alzheimer’s disease.
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We fit a linear regression equation to the log of the age-specific incidence rate for each of 27
studies in our review because incidence rates appeared to grow exponentially with age. We then
averaged the rates from the fitted regression lines to obtain an equation for the age-specific
incidence rate. We found that the annual age-specific incidence of Alzheimer’s disease at age t
expressed in per cent per year (for t greater than 60) is given by:
.121( t − 60 )

Incidence rate (% per year) = .132e

.

(1)

Equation 1 implies that incidence grows exponentially with a doubling time of about 5.7 years.
We found no significant geographic differences in the doubling times of Alzheimer’s incidence
(p=.3), suggesting that any geographic variation may be due to different criteria and thresholds
for diagnosis. We used equation 1 for the incidence rates (rt,y in figure 1) in our analyses. We
accounted for uncertainty in equation 1 by performing a sensitivity analysis that used a range
based on the upper and lower 10th percentiles of the distribution of fitted incidence rates from all
the studies. This range spanned from about half to double the incidence estimates from equation
1. For example, the predicted annual incidence at age 80 is 1.48 % per year with range of 0.67%
to 3.41%. The ranges we cite in the results section account for this uncertainty in incidence
rates. We also performed sensitivity analyses to the assumption that incidence continues to grow
exponentially at the oldest ages by holding incidence rates constant after age 90.
Disease Progression
Alzheimer’s disease is a progressive disease and persons who have the disease longer
often require a higher level of care. Considerable variability exists in the world’s literature on
the rate of Alzheimer’s disease progression which results from differences in definitions of
severe disease among studies, and heterogeneity in the disease course among patients. The
Consortium to Establish a Registry for Alzheimer’s disease suggested that 6 years is the mean
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time from mild to severe disease using the Clinical Dementia Rating scale (5). Similarly, a study
examining the time for patients needing care equivalent to placement in a health related facility,
such as a nursing home, also obtained an estimate of about 6 years (7). We defined late stage
disease to refer to the period when patients need such a high level of care. We used an annual
transition probability from early to late stage disease of .167 in our model which corresponds to a
mean duration of early stage disease of approximately 6 years. The model accounts for
variability in the duration of early disease course (the 25th, 50th and 75th percentiles of the
distribution of durations of early stage disease are approximately 1.7, 4.2 and 8.3 years
respectively). We performed sensitivity analyses to the underlying disease progression rate (γ)
We recognize that the rate of disease progression could depend on age or gender; however, we
do not believe at this time the epidemiological data is sufficient to more precisely characterize
rates of disease progression.
Death rates
We assumed that the effect of Alzheimer’s disease was to increase the background
mortality rates (dty). We modeled this excess mortality by an additive model for the death rates
whereby the death rates for patients with late stage disease (d*) are:

d ty* = d ty + k

(2)

where d are the background mortality rates, and k is the excess mortality associated with
Alzheimer’s disease (the subscripts indicate that the model accounts for age (t) and calendar year
(y)). Then, we calibrated the parameter k to published studies on Alzheimer’s survival using least
squares and obtained k =.11. For example, the model predicted that the median survival times
for males diagnosed with Alzheimer’s at ages 65, 75 and 85 were 7.9, 5.7 and 3.3 years,
respectively; the predicted median survival times for females diagnosed at ages 65, 75 and 85
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were 9.1, 7.2 and 4.3 years respectively. These model predictions are in good agreement with
published studies on Alzheimer’s disease (8-10), and in fact were within 6 months of empirical
findings (10). The interpretation of this model is that the effect of Alzheimer’s disease on
mortality is to add 11% per year to the background mortality rates once the disease has
progressed to late stage. We also performed sensitivity analyses to evaluate the effect of excess
mortality over background during both early and late stage disease.
We assembled U.S. death rates by gender and age from 1959 to the present as a basis for
the background death rates (dty) (11). We recognize that variation is considerable in background
mortality rates throughout the world. Accordingly, we performed sensitivity analyses of our
results to these background mortality rates. Forecasts of disease prevalence also require
assumptions about the background mortality rates into the future. We extrapolated recent past
trends in mortality to obtain predictions of future mortality rates. We fit regression models to the
mortality rates over a 15 year period (between 1988 and 2002) for each year of age, to obtain
estimates of the annual percent change in mortality rates that were then used to predict future
background mortality.
.

RESULTS
In 2006, there were 26.6 million cases of Alzheimer’s disease in the world (range 11.459.4). We predict that by the year 2050 the worldwide prevalence of Alzheimer’s will grow
fourfold to 106.8 million (range 47.2-221.2). Table 1 shows the geographic distribution of the
burden of disease. We estimate that 48% of the worldwide cases are in Asia and that percentage
will grow to 59% by 2050.
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Figure 2 shows the 2006 age-specific prevalence rates of Alzheimer’s derived from our
model. For example, the prevalence rates at ages 65, 75 and 85 were 0.9%, 4.2% and 14.7%
respectively. Figure 2 also shows the age-specific prevalence rate by stage of disease from
which one can calculate the percent of cases with late stage disease. For example, the model
predicts the percentage of 65 year old cases with late stage disease is 34% and increases to 45%
among 85 year old cases. Overall, we estimate about 11.6 (43%) of the 26.6 million worldwide
cases living today have late stage disease (table 1). Figure 3 shows the growth in the prevalence
of Alzheimer’s disease cases through 2050 by stage of disease and by gender. We estimate that
about 62% of worldwide cases are female reflecting the lower background mortality rates among
women.
We evaluated the potential effects of interventions that could either delay disease onset or
disease progression under 6 scenarios. Prevention programs that could delay onset by 1 or 2
years correspond to a relative risk (i.e., the multiplier of the transition probability) of .88 and .77
respectively. Therapeutic treatment interventions that delay disease progression by 1 and 2 years
correspond to relative risks of .85 and .75 respectively. Table 2 shows the effects that such
interventions could have on the global burden of Alzheimer’s disease by the year 2050.
Delaying disease onset by an average of 2 years would decrease worldwide prevalence of
Alzheimer’s by 22.8 million cases (scenario A). Even a modest one year delay in disease onset
would result in 11.8 million fewer cases worldwide (scenario B). A therapeutic intervention that
delays disease progression by an average of 2 years with no effect on disease onset would
actually result in a net increase in global prevalence of 5.2 million cases because of a rise in the
number of early stage cases (scenario C). However, under scenario C, there would also be a
decrease of nearly 7 million late stage cases. Interventions even modestly delaying both disease
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onset and progression can significantly decrease the global burden of disease. For example, if
both disease onset and disease progression are delayed by 1 year (scenario F) , there would be
nearly 9.2 million fewer cases of disease and nearly all of that decline is attributed to decreases
in the numbers of cases with late stage disease.
The sensitivity of our results were evaluated with respect to a number of model
assumptions. Equation 1 assumes that the age-specific incidence rate continues to grow
exponentially even in the oldest ages. If however, incidence rates plateau and remain constant
after age 90 instead of continuing to raise exponentially, then a modest 4% decline is observed
for the 2050 estimate of the worldwide prevalence of Alzheimer’s disease. We find that
estimates of worldwide prevalence are not especially sensitive to the shape of the incidence
curve at the oldest ages because the oldest ages represent a relatively small segment of the
population.
Sensitivity of our results to the background death rates was also examined. Surprisingly,
when the background mortality rates were inflated by 20%, the absolute age-specific prevalence
rates in figure 2 decreased very slightly, in fact by at most 3 per 1000. While surprising that the
model for the age specific prevalence rates is not sensitive to the background mortality rates, the
reason is that the age-specific prevalence rate is the ratio of persons with disease to persons alive,
and if the background death rates increase, then both the numerator and denominator decrease,
and the net effect is that the ratio itself does not change much.
We also considered the sensitivity of our results to our model for Alzheimer’s mortality.
Initially, we had assumed that excess mortality from Alzheimer’s occurred only during late stage
disease. If excess mortality also occurs during early stage of disease which was say, half the
excess of that in late stage disease (i.e., we added k/2 to the background death rates in early
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stage) , our estimate of worldwide prevalence in 2006 would decline by about 14%, and the
percentage of cases classified as late stage would slightly increase from 43% to 46%.
We considered the sensitivity of our results to the progression rate from early to late stage
disease. If the average duration of early stage disease was in fact greater than the 6 years we
assumed, then the percentage of prevalent cases that have late stage disease should be smaller
than estimated. That phenomenon reflects the epidemiological concept that prevalence increases
with duration. For example, if the mean durations of early stage disease were 4, 6, and 8 years,
then with all other factors fixed) the estimated worldwide prevalence in 2006 of late stage
Alzheimer’s disease would be 13.9, 11.6 and 9.8 million cases respectively; and the percentages
of prevalent cases that are classified as late stage would be 56%, 43% and 35% respectively.

DISCUSSION
Our model indicates that 26.6 million persons worldwide are currently living with
Alzheimer’s disease (range 11.4 to 59.4). We project that by the year 2050 worldwide prevalence
will quadruple to 106.2 million with 1 in 85 persons living with Alzheimer’s disease. The
increase is a result of the aging of the world’s population. The United Nations Population
Division projects that the number of persons at least 80 years of age will increase by a factor of
about 3.7 by the year 2050. The Alzheimer’s Disease International study concluded there were
24.3 million persons with dementia in the world using a Delphi consensus methodology (2).
Wimo and colleagues (12) estimated 25.5 million cases of dementia worldwide in 2000 by
multiplying age-specific prevalence rates derived from epidemiological surveys by population
estimates. Our estimates, which refer specifically to Alzheimer’s disease cases rather than
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dementia more generally, are broadly consistent with these estimates which were obtained using
different methodologies.
An advantage of the modeling methodology used in this paper is that the effects of
interventions may be evaluated. We find that the impact of interventions depend on whether the
interventions delay onset of disease, delay progression of disease, or a combination of both.
Interventions can differentially affect the stage-specific prevalence depending on which stage of
the disease natural history is targeted. We find that interventions that both delay disease onset
and delay progression by even a modest amount would result in significant reductions in the
global burden of disease. In related work, Sloane and colleagues (13) evaluated the impact of
therapeutic advances in the United States. They found, as did we, that therapies that only delayed
disease progression would lead to a decrease in advanced disease. But they also found no overall
increase in Alzheimer’s prevalence which was in contrast to our finding of a net increase
(scenario C in table 2). We find that therapeutic advances that delay disease progression would
lead to an increase in overall disease prevalence but on average the prevalent cases would have
less severe disease.
There are important sources of uncertainty in our results. Main sources of uncertainty are
the age-specific Alzheimer’s disease incidence rates, which are reflected in the wide ranges of
our forecasts. Data was not sufficient to obtain separate incidence rates for each geographic
region, and we used equation 1 for all regions. The majority of published studies on age specific
incidence rates of Alzheimer’s disease are derived from populations in developed countries, and
there is a critical need for additional studies in developing countries. We cannot say whether
geographic variation in Alzheimer’s incidence rates result from real differences in underlying
incidence or rather differences in methodology and diagnostic criteria of the epidemiological
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studies. Our wide ranges on our estimates account for this uncertainty. However, we did not
find any significant geographic differences in the doubling times of the age specific incidence
rates. Accordingly, our finding about the proportionate increase in Alzheimer’s disease, namely
a quadrupling in prevalence by 2050, is reasonably precise, even if the absolute number of cases
is more uncertain. Indeed, we conclude Alzheimer’s disease prevalence will quadruple by 2050
regardless of whether we use the lower or upper limits of our range of disease incidence rates.
That conclusion does however depend on the accuracy of the U.N demographic projections of
the aging of the world population.
The resources needed to care for an Alzheimer’s patient depends on stage of disease.
Adult day care programs may be adequate in the early stages, while a high level of care,
equivalent to that of nursing homes, will be needed in the late stages. Assessments of the global
burden of disease should account for disease stage. We recognize that currently there is no single
staging system that is accurate, reproducible and routinely used worldwide. Nevertheless, we
believe the two stage model of disease progression used here, produces useful estimates of the
numbers of patients requiring a high level of care roughly equivalent to that provided by a health
care facility such as a nursing home. Epidemiological surveys of the percentage of cases with
severe disease have ranged between 2% to over 50% (14-16). Such wide variation could result
either from differences in survey methodology and diagnostic criteria, or sampling enrollment
biases. Our modeling approach produces estimates in the upper end of the range. As more
information becomes available about disease progression rates the multi-state model can be used
with updated input parameters for the transition probabilities. A web site that allows users to
input their own transition probabilities and population data, and then implements the multi-state

13
Hosted by The Berkeley Electronic Press

model to obtain forecasts of the global burden of Alzheimer’s disease is available from the
authors.
As the world’s population ages, we will face a looming epidemic of Alzheimer’s disease.
Health care systems will be challenged to meet the needs of patients and their caregivers. The
worldwide costs will be huge (17). Prevention of Alzheimer’s is an ambitious goal (1, 18) that
may not be fully achievable in the near term, although delaying disability may be achievable.
We find that modest advances in therapeutic and preventive strategies resulting in even small
delays in Alzheimer’s disease onset and progression can significantly reduce the global burden
of the disease.
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Table 1:
Projections of Alzheimer’s disease prevalence (in millions) in 2006 and 2050 by regions and stage of disease
Prevalence (in millions)

Africa

1.33

2006
Early
Stage
0.76

Asia

12.65

7.19

5.56

62.85

34.84

28.01

Europe

7.21

4.04

3.17

16.51

9.04

7.47

Latin Am. / Caribbean

2.03

1.14

0.89

10.85

5.99

4.86

North America

3.10

1.73

1.37

8.85

4.84

4.01

Oceania

0.23

0.13

0.10

0.84

0.46

0.38

Total

26.55

14.99

11.56

106.23

58.75

47.48

Overall

6.33

2050
Early
Stage
3.58

Late
Stage
2.75

Late
Stage
0.57

Overall

Note: Regions defined according to the United Nations Population Division (4):Oceania includes Australia, New
Zealand, Melanesia, Micronesia, and Polynesia.
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Table 2:
Impact of interventions on world-wide prevalence of Alzheimer’s disease. Table shows change in prevalence in
2050 associated with interventions begun in 2010 compared to baseline scenario of no intervention.
Intervention
Scenario
A

Mean Delay
(in years)
Onset
Progression
2
0

Change in Worldwide Prevalence
(in millions)
Overall
Early Stage
Late Stage
- 22.76
- 12.28
- 10.48

B

1

0

- 11.76

- 6.32

- 5.44

C

0

2

+ 5.23

+ 12.14

- 6.91

D

0

1

+ 2.84

+ 6.54

- 3.70

E

2

2

- 18.48

- 2.66

- 15.82

F

1

1

- 9.19

- 0.48

- 8.71

Note: These estimates refer to the changes in prevalence compared to the baseline scenario of no
intervention. Under the baseline scenario of no intervention, in 2050 there will be 106.23
million cases worldwide of which 58.75 and 47.48 million cases have early and late stage disease
respectively (from Table 1).

.
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LIST OF FIGURES
Figure 1: Multi-state model of progression of Alzheimer’s disease. The transition probabilities
shown are the disease incidence rates (r), disease progression rates (γ) and death
rates (d) .which can depend on age (t) and calendar year (y).
Figure 2: Age-specific prevalence rates for Alzheimer’s disease derived from multi-state
model.
Figure 3: World-wide Projections of Alzheimer’s prevalence (in millions), 2006-2050 by stage
of disease: (a) males ((b) females.
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